| Japanese |
|---|
| Title | 111In - ペンテトレオチドによるソマトスタチン受容体イメージングの臨床試験 |
|---|
| Subtitle | 技術報告 |
|---|
| Authors | 木村利幸*, 阪原晴海*, 東達也*, 本田豊彦*, 小西淳二*, 細谷亮**, 大塩学而**, 今村正之**, 猪熊哲朗*** |
|---|
| Authors(kana) | |
|---|
| Organization | *京都大学医学部核医学科, **第一外科, ***大阪逓信病院第一内科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 33 |
|---|
| Number | 4 |
|---|
| Page | 447-452 |
|---|
| Year/Month | 1996/4 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」111In-ペンテトレオチドを用いるソマトスタチン受容体イメージングの臨床試験を胃カルチノイド腫瘍1例, 胃十二指腸動脈領域にガストリノーマの存在が疑われる1例, 組織診断の確定したガストリノーマ肝転移2例の計4症例に対して行った. 組織診断の確定したガストリノーマ肝転移2例では, 原発巣および転移巣ともに111In-ペンテトレオチドの良好な集積が見られた. うち1例ではCT, MRIでは検出されなかった肝転移巣が陽性に描出された. 胃カルチノイド腫瘍例, 胃十二指腸動脈領域にガストリノーマの存在が疑われる症例では, 病巣を描出できなかった. 111In-ペンテトレオチド投与による重篤な副作用は認められなかった. 111In-ペンテトレオチドシンチグラフィは, ソマトスタチン受容体を有する腫瘍の診断に有用と思われた. 「I. はじめに」消化管ホルモン産生腫瘍は, 従来の画像診断ではしばしばその病変の局在診断が困難である. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | [111In]pentetreotide, Somatostatin, Receptor imaging, Gastrinoma, Carcinoid tumor. |
|---|
| English |
|---|
| Title | Imaging of Somatostatin Receptor Using 111In - Pentetreotide |
|---|
| Subtitle | Technical Reports |
|---|
| Authors | Akio KOMATANI*, Tooru AKUTSU*, Koichi YAMAGUCHI*, Yuuya ONODERA*, Yukiko MANAKA**, Kazuei TAKAHASHI** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Nuclear Medicine, Kyoto University School of Medicine, **First Department of Surgery, Kyoto University School of Medicine, ***First Department of Internal Medicine, Osaka Teishin Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 33 |
|---|
| Number | 4 |
|---|
| Page | 447-452 |
|---|
| Year/Month | 1996/4 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]Recently radiolabeled somatostatin analog, [111In]pentetreotide, was developed and its usefulness for the diagnosis and localization of neuroendocrine tumors has been described. In this paper, we reported the results of [111In]Pentetreotide scintigraphy in four patients with gastroenteropancreatic endocrine tumors. Two patients with metastatic gastrinoma, one patient with gastric carcinoid, and one patient suspected with gastrinoma, were injected with 119-156MBq of[111In] pentetreotide. Planar and SPECT images were obtained 4, 24, and 48 hours postinjection. Both primary and metastatic tumors were well visualized in patients with metastatic gastrinoma. Especially in one patient small liver metastases which were not detected by CT or MRI were imaged. We could not obtain positive images in the other two patients. Fourhour or 24-hr images were better than 48-hr images because of higher count density and lower gut activity. No significant adverse effect were seen in any patient. [111In]pentetreotide scintigraphy is a useful procedure for the localization of gastroenteropancreatic endocrine tumors. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | [111In]pentetreotide, Somatostatin, Receptor imaging, Gastrinoma, Carcinoid tumor. |
|---|